Display options
Cite
Mehta R, Otgonsuren M, Younoszai Z, et al. Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ Open Gastroenterol. 2016;3(1):e000096doi: 10.1136/bmjgast-2016-000096.
Mehta, R., Otgonsuren, M., Younoszai, Z., Allawi, H., Raybuck, B., & Younossi, Z. (2016). Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ open gastroenterology, 3(1), e000096. https://doi.org/10.1136/bmjgast-2016-000096
Mehta, Rohini, et al. "Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease." BMJ open gastroenterology vol. 3,1 (2016): e000096. doi: https://doi.org/10.1136/bmjgast-2016-000096
Mehta R, Otgonsuren M, Younoszai Z, Allawi H, Raybuck B, Younossi Z. Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ Open Gastroenterol. 2016 Jul 26;3(1):e000096. doi: 10.1136/bmjgast-2016-000096. eCollection 2016. PMID: 27493762; PMCID: PMC4964159.
Copy Download .nbib Format: NLM
Share it on

BMJ Open Gastroenterol. 2016 Jul 26;3(1):e000096. doi: 10.1136/bmjgast-2016-000096. eCollection 2016.

Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease.

BMJ open gastroenterology

Rohini Mehta, Munkzhul Otgonsuren, Zahra Younoszai, Hussain Allawi, Bryan Raybuck, Zobair Younossi

Affiliations

  1. Betty and Guy Beatty Center for Integrated Research, Inova Fairfax Medical Campus , Falls Church, Virginia , USA.

PMID: 27493762 PMCID: PMC4964159 DOI: 10.1136/bmjgast-2016-000096

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and coronary artery disease (CAD) is the cardiac manifestation of metabolic syndrome. NAFLD is strongly linked to CAD and hepatic steatosis is an independent risk factor for CAD and cardiac mortality. The pathogenic mechanism underlying this association remains poorly understood. In this study, we explored expression of circulating microRNAs (miRNAs) in patients with NAFLD and associated CAD.

RESULTS: When compared to patients with NAFLD without CAD, patients with NAFLD and CAD had lower circulating levels of miR-132 (0.24±0.16 vs 0.30±0.11, p=0.03), while the circulating levels of miR-143 were higher (0.96±0.90 vs 0.64±0.77, p=0.02). The levels in circulation demonstrated trends opposite to previously observed intracellular levels in patients with CAD. In obese patients with NAFLD, lower circulating levels of miR-145 (1.42±1.00 vs 2.41±1.80), miR-211 (41.26±20.40 vs 57.56±25.45), miR-146a (2.13±1.40 vs 2.90±1.36) and miR-30c (6.92±4.99 vs 11.0±6.92) were detected when compared to lean patients with NAFLD. For miR-161 (0.59±1.19 vs 0.15±0.14) and miR-241 (0.28±0.29 vs 0.16±0.13), higher circulatory levels were detected in the obese patients with NAFLD. These observations suggest altered circulating levels of miRNAs that may serve to balance intracellular levels of miRNA in target tissues. Additional studies examining paired samples of target and producing tissues as well as respective plasma samples will help delineate the regulatory circuits governing the secretion and the uptake of miRNA in multitissue diseases.

Keywords: CARDIOVASCULAR DISEASE; GENE REGULATION; LIVER

References

  1. Mol Cell. 2010 Jul 9;39(1):133-44 - PubMed
  2. Hepatology. 2003 Apr;37(4):917-23 - PubMed
  3. World J Gastroenterol. 2007 Mar 14;13(10 ):1579-84 - PubMed
  4. Cardiovasc Res. 2012 Mar 15;93(4):633-44 - PubMed
  5. Dis Markers. 2013;34(3):163-9 - PubMed
  6. Cell Mol Life Sci. 2012 Mar;69(5):793-808 - PubMed
  7. PLoS One. 2010 Oct 20;5(10):e13515 - PubMed
  8. FEBS Lett. 2011 Feb 18;585(4):657-63 - PubMed
  9. Eur J Pharmacol. 2015 Aug 15;761:375-82 - PubMed
  10. Br J Cancer. 2015 Jul 14;113(2):275-81 - PubMed
  11. Cell Res. 2008 Oct;18(10):997-1006 - PubMed
  12. Gut. 2011 Dec;60(12 ):1721-7 - PubMed
  13. Aliment Pharmacol Ther. 2014 Jan;39(1):3-14 - PubMed
  14. Clin Sci (Lond). 2014 Jan;126(2):95-110 - PubMed
  15. Blood. 2011 Dec 22;118(26):6793-802 - PubMed
  16. PLoS One. 2011;6(6):e20769 - PubMed
  17. PLoS One. 2010 Oct 08;5(10):e13247 - PubMed
  18. Cancer Prev Res (Phila). 2012 Mar;5(3):492-7 - PubMed
  19. Arch Cardiovasc Dis. 2008 Sep;101(9):577-83 - PubMed
  20. Nucleic Acids Res. 2010 Nov;38(20):7248-59 - PubMed
  21. Circ Res. 2007 Jun 8;100(11):1579-88 - PubMed
  22. Hum Mol Genet. 2011 Feb 15;20(4):731-51 - PubMed
  23. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1224-9, 1229.e1-2 - PubMed
  24. Genes Dev. 2009 Sep 15;23(18):2166-78 - PubMed
  25. QJM. 2010 Feb;103(2):71-83 - PubMed
  26. J Clin Invest. 1983 Jun;71(6):1854-66 - PubMed
  27. Hepatology. 2009 May;49(5):1537-44 - PubMed
  28. Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):542-52 - PubMed
  29. Commun Integr Biol. 2010 Sep;3(5):478-81 - PubMed
  30. Angiology. 2013 Nov;64(8):604-8 - PubMed
  31. Clin Chem. 2010 Nov;56(11):1733-41 - PubMed
  32. PLoS One. 2008;3(11):e3694 - PubMed
  33. Immunity. 2009 Dec 18;31(6):965-73 - PubMed
  34. Dig Dis Sci. 2011 Dec;56(12):3439-49 - PubMed
  35. Trends Biochem Sci. 2012 Nov;37(11):460-5 - PubMed
  36. Genes Dis. 2014 Mar 1;1(1):18-39 - PubMed
  37. Circ Cardiovasc Genet. 2011 Apr;4(2):197-205 - PubMed
  38. Aliment Pharmacol Ther. 2010 Aug;32(3):487-97 - PubMed
  39. Nucleic Acids Res. 2012 Jun;40(11):4742-53 - PubMed
  40. Hippokratia. 2010 Oct;14(4):236-40 - PubMed
  41. Mol Endocrinol. 2009 Nov;23(11):1876-84 - PubMed
  42. Cell Death Differ. 2009 Dec;16(12):1590-8 - PubMed
  43. Cell. 2009 Jan 23;136(2):215-33 - PubMed
  44. Mol Carcinog. 2011 Feb;50(2):136-42 - PubMed
  45. Dis Markers. 2015 ;2015 :625659 - PubMed
  46. PLoS One. 2013 Oct 15;8(10):e77251 - PubMed
  47. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 - PubMed
  48. Annu Rev Genomics Hum Genet. 2007;8:215-39 - PubMed
  49. World J Gastroenterol. 2011 Sep 7;17(33):3785-94 - PubMed
  50. Cardiovasc Res. 2016 Feb 1;109 (2):228-39 - PubMed
  51. Metabolism. 2016 Aug;65(8):1136-50 - PubMed

Publication Types